Home › NDC Lookup › RxCUI directory › RxCUI 2726055

Lisdexamfetamine dimesylate 10 MG/ML Oral Solution [Arynta] — RxCUI 2726055

RxNorm drug concept · Semantic branded drug
RxCUI 2726055 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2726055
Official nameLisdexamfetamine dimesylate 10 MG/ML Oral Solution [Arynta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asArynta 10 MG/ML Oral Solution; Arynta 10 MG in 1 mL Oral Solution; Arynta 10 MG per 1 ML Oral Solution
FDA products mapped5
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lisdexamfetamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lisdexamfetamine is used to treat two conditions: ADHD in adults and kids age 6 and older, and moderate to severe binge eating disorder in adults. It's not approved for weight loss...
  • What exactly is lisdexamfetamine used for?
  • The most common ones are decreased appetite, trouble sleeping, dry mouth, nausea, and weight loss. Some people also feel jittery or anxious, especially early on. Most of these tend...
  • What are the most common side effects I should expect?
📖 Read our full Lisdexamfetamine guide →

🕸️ Concept Web — How Lisdexamfetamine dimesylate 10 MG/ML Oral Soluti... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lisdexamfetamine dimesylate 10 MG/ML Oral Solution [Arynta] RxCUI 2726055

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Lisdexamfetamine 700810
    • Lisdexamfetamine dimesylate 673579
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Arynta 2726049
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lisdexamfetamine Oral Solution 2726045
    • Lisdexamfetamine dimesylate Oral Solution 2726047
    • Lisdexamfetamine Oral Liquid Product 2726044
    • Lisdexamfetamine Oral Product 1164687
    • Lisdexamfetamine dimesylate Oral Liquid Product 2726046
    • Lisdexamfetamine dimesylate Oral Product 2663335
    • Lisdexamfetamine Oral Solution [Arynta] 2726053
    • Lisdexamfetamine dimesylate Oral Solution [Arynta] 2726054
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lisdexamfetamine dimesylate 10 MG/ML Oral Solution SCD · 2726048
  • Lisdexamfetamine dimesylate 10 MG/ML SCDC · 2726043
  • Lisdexamfetamine Oral Solution SCDF · 2726045
  • Lisdexamfetamine dimesylate Oral Solution SCDFP · 2726047
  • Lisdexamfetamine Oral Liquid Product SCDG · 2726044
  • Lisdexamfetamine Oral Product SCDG · 1164687
  • Lisdexamfetamine dimesylate Oral Liquid Product SCDGP · 2726046
  • Lisdexamfetamine dimesylate Oral Product SCDGP · 2663335

Brand-Name Concepts

  • Lisdexamfetamine dimesylate 10 MG/ML [Arynta] SBDC · 2726050
  • Lisdexamfetamine Oral Solution [Arynta] SBDF · 2726053
  • Lisdexamfetamine dimesylate Oral Solution [Arynta] SBDFP · 2726054
  • Arynta Oral Liquid Product SBDG · 2726052
  • Arynta Oral Product SBDG · 2726051
  • Arynta BN · 2726049

📦 FDA Products & Package NDCs

5 products · 5 package NDCs
5 package NDCs map to RxCUI 2726055 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0019-01 1 BOTTLE in 1 CARTON (24338-019-01) / 100 mL in 1 BOTTLE ARYNTA Azurity Pharmaceuticals, Inc. 2026-03-20
24338-0103-01 1 BOTTLE in 1 CARTON (24338-103-01) / 30 mL in 1 BOTTLE ARYNTA Azurity Pharmaceuticals, Inc. 2026-03-20
24338-0109-01 1 BOTTLE in 1 CARTON (24338-109-01) / 90 mL in 1 BOTTLE ARYNTA Azurity Pharmaceuticals, Inc. 2026-03-20
24338-0160-01 1 BOTTLE in 1 CARTON (24338-160-01) / 60 mL in 1 BOTTLE ARYNTA Azurity Pharmaceuticals, Inc. 2026-03-20
24338-0162-01 1 BOTTLE in 1 CARTON (24338-162-01) / 120 mL in 1 BOTTLE ARYNTA Azurity Pharmaceuticals, Inc. 2026-03-20
Observed labelers: Azurity Pharmaceuticals, Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.